Business Context and Reporting Period
This Form 8-K was filed by AmerisourceBergen Corporation (now Cencora, Inc.) on November 1, 2012. The report announces financial results for the fiscal quarter and full year ended September 30, 2012, and provides forward-looking guidance for fiscal year 2013.
Key Financial Metrics
- Fiscal 2012 Diluted EPS: $2.80 total, including $0.04 from discontinued operations (AndersonBrecon).
- Fiscal 2013 Free Cash Flow Guidance: $750 million to $850 million.
- Fiscal 2013 Capital Expenditures: Approximately $180 million.
- Share Repurchases: Expectation to spend approximately $200 million in fiscal 2013; a new $750 million share repurchase program was approved.
- Dividend: Board approved a 62% increase in the annual dividend rate.
Material Changes and Strategic Actions
- Divestiture: The company is pursuing the sale of AndersonBrecon, its contract pharmaceutical packaging business, to focus on distribution, specialty, and manufacturer services. Income from this unit is classified as discontinued operations.
- Capital Allocation: Significant increase in shareholder returns via a 62% dividend hike and a new $750 million buyback authorization.
Guidance and Outlook
Management provided the following expectations for fiscal year 2013:
- Diluted EPS (Continuing Operations): $3.06 to $3.16.
- Revenue Growth: 6% to 9%.
- Operating Income Growth: 3% to 5%.
- Operating Margin: Expected to decline by low double-digit basis points.
Investor Verification Checklist
- Verify the specific dollar amount of the new annual dividend rate following the 62% increase.
- Confirm the timeline and status of the AndersonBrecon sale transaction.
- Review the detailed breakdown of the $2.80 fiscal 2012 EPS to isolate continuing operations performance.
- Monitor the execution of the new $750 million share repurchase program against the $200 million initial spending expectation.